pazopanib zentiva õhukese polümeerikattega tablett
zentiva k.s. - pasopaniib - õhukese polümeerikattega tablett - 400mg 60tk
pazopanib zentiva õhukese polümeerikattega tablett
zentiva k.s. - pasopaniib - õhukese polümeerikattega tablett - 200mg 90tk
pazopanib accord õhukese polümeerikattega tablett
accord healthcare b.v. - pasopaniib - õhukese polümeerikattega tablett - 200mg 30tk; 200mg 90tk
pazopanib accord õhukese polümeerikattega tablett
accord healthcare b.v. - pasopaniib - õhukese polümeerikattega tablett - 400mg 30tk; 400mg 10tk; 400mg 60tk
leflunomide elvim õhukese polümeerikattega tablett
sia elvim - leflunomiid - õhukese polümeerikattega tablett - 10mg 30tk
leflunomide elvim õhukese polümeerikattega tablett
sia elvim - leflunomiid - õhukese polümeerikattega tablett - 20mg 30tk
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
teriflunomide teva õhukese polümeerikattega tablett
teva b.v. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 14tk; 14mg 28tk; 14mg 30tk; 14mg 84tk
sivextro
merck sharp & dohme b.v. - tedisolidfosfaat - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.
terebyo õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 84tk; 14mg 28tk